+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Research Report 2022 (Status and Outlook)

  • ID: 5590960
  • Report
  • March 2022
  • Region: Global
  • 112 Pages
  • Bosson Research

FEATURED COMPANIES

  • Abbott
  • Allergan
  • Astellas Pharma
  • Eli Lilly
  • GlaxoSmithKline
  • Merck
The Global Benign Prostatic Hyperplasia (BPH) Drugs Market was estimated at USD 3,323.6 million in 2021 and is projected to reach USD 3,538.8 million by 2028, exhibiting a CAGR of 0.90% during the forecast period.



This research report provides a deep insight into the global Benign Prostatic Hyperplasia (BPH) Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Benign Prostatic Hyperplasia (BPH) Drugs Market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Benign Prostatic Hyperplasia (BPH) Drugs market in any manner.

Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Market Segmentation Analysis


The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in a product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Companies

  • Eli Lilly
  • GlaxoSmithKline
  • Astellas Pharma
  • Sanofi
  • Pfizer
  • Abbott
  • Allergan
  • TEVA
  • Mylan
  • Novartis
  • Merck

Market Segmentation (by Type)

  • Alpha-Blocker
  • Phosphodiesterase Type-5 Inhibitors
  • Others

Market Segmentation (by Application)

  • Hospitals
  • Drugstores
  • Others

Geographic Segmentation

  • North America (USA, Canada, Mexico)
  • Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
  • South America (Brazil, Argentina, Columbia, Rest of South America)
  • The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research

  • Industry drivers, restraints, and opportunities covered in the study
  • Neutral perspective on the market performance
  • Recent industry trends and developments
  • Competitive landscape & strategies of key players
  • Potential & niche segments and regions exhibiting promising growth covered
  • Historical, current, and projected market size, in terms of value
  • In-depth analysis of the Biobased Transformer Oil Market
  • Overview of the regional outlook of the Benign Prostatic Hyperplasia (BPH) Drugs Market

Key Reasons to Buy this Report

  • Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
  • This enables you to anticipate market changes to remain ahead of your competitors
  • You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
  • The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
  • Provision of market value (USD Billion) data for each segment and sub-segment
  • Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
  • Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
  • Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
  • Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
  • The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
  • Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
  • Provides insight into the market through Value Chain
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • 6-month post-sales analyst support

Customization of the Report


In case of any queries or customization requirements, please contact the customer services department, who will ensure that your requirements are met.

Chapter Outline

  • Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
  • Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view of the current state of the cell-based therapy manufacturing market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on.
  • Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
  • Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
  • Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
  • Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
  • Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
  • Chapter 12 is the main points and conclusions of the report.
Frequently Asked Questions about the Global Benign Prostatic Hyperplasia (BPH) Drugs Market

What is the estimated value of the Global Benign Prostatic Hyperplasia (BPH) Drugs Market?

The Global Benign Prostatic Hyperplasia (BPH) Drugs Market was estimated to be valued at $3323.6 Million in 2021.

What is the growth rate of the Global Benign Prostatic Hyperplasia (BPH) Drugs Market?

The growth rate of the Global Benign Prostatic Hyperplasia (BPH) Drugs Market is 0.8%, with an estimated value of $3538.8 Million by 2028.

What is the forecasted size of the Global Benign Prostatic Hyperplasia (BPH) Drugs Market?

The Global Benign Prostatic Hyperplasia (BPH) Drugs Market is estimated to be worth $3538.8 Million by 2028.

Who are the key companies in the Global Benign Prostatic Hyperplasia (BPH) Drugs Market?

Key companies in the Global Benign Prostatic Hyperplasia (BPH) Drugs Market include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA and Novartis.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott
  • Allergan
  • Astellas Pharma
  • Eli Lilly
  • GlaxoSmithKline
  • Merck

?1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Benign Prostatic Hyperplasia (BPH) Drugs
1.2 Key Market Segments
1.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
1.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Benign Prostatic Hyperplasia (BPH) Drugs Market Overview
2.1 Global Market Overview
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size (M USD) Estimates and Forecasts (2017-2028)
2.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Estimates and Forecasts (2017-2028)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Landscape
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2017-2022)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturers (2017-2022)
3.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Manufacturers (2017-2022)
3.5 Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Sales Sites, Area Served, Product Type
3.6 Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation and Trends
3.6.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Benign Prostatic Hyperplasia (BPH) Drugs Industry Chain Analysis
4.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Chain Analysis
4.2 Market Overview and Market Concentration Analysis of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Benign Prostatic Hyperplasia (BPH) Drugs Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Benign Prostatic Hyperplasia (BPH) Drugs Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2017-2022)
6.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Market Share by Type (2017-2022)
6.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2017-2022)
7 Benign Prostatic Hyperplasia (BPH) Drugs Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Sales by Application (2017-2022)
7.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size (M USD) by Application (2017-2022)
7.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Application (2017-2022)
8 Benign Prostatic Hyperplasia (BPH) Drugs Market Segmentation by Region
8.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
8.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
8.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region
8.2 North America
8.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profiled
9.1 Eli Lilly
9.1.1 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
9.1.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
9.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Market Performance
9.1.4 Eli Lilly Business Overview
9.1.5 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs SWOT Analysis
9.1.6 Eli Lilly Recent Developments
9.2 GlaxoSmithKline
9.2.1 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
9.2.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
9.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Market Performance
9.2.4 GlaxoSmithKline Business Overview
9.2.5 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs SWOT Analysis
9.2.6 GlaxoSmithKline Recent Developments
9.3 Astellas Pharma
9.3.1 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
9.3.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
9.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Market Performance
9.3.4 Astellas Pharma Business Overview
9.3.5 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs SWOT Analysis
9.3.6 Astellas Pharma Recent Developments
9.4 Sanofi
9.4.1 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
9.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
9.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Market Performance
9.4.4 Sanofi Business Overview
9.4.5 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs SWOT Analysis
9.4.6 Sanofi Recent Developments
9.5 Pfizer
9.5.1 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
9.5.2 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
9.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Market Performance
9.5.4 Pfizer Business Overview
9.5.5 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs SWOT Analysis
9.5.6 Pfizer Recent Developments
9.6 Abbott
9.6.1 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
9.6.2 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
9.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Market Performance
9.6.4 Abbott Business Overview
9.6.5 Abbott Recent Developments
9.7 Allergan
9.7.1 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
9.7.2 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
9.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Market Performance
9.7.4 Allergan Business Overview
9.7.5 Allergan Recent Developments
9.8 TEVA
9.8.1 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
9.8.2 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
9.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Market Performance
9.8.4 TEVA Business Overview
9.8.5 TEVA Recent Developments
9.9 Mylan
9.9.1 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
9.9.2 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
9.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Market Performance
9.9.4 Mylan Business Overview
9.9.5 Mylan Recent Developments
9.10 Novartis
9.10.1 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
9.10.2 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
9.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Market Performance
9.10.4 Novartis Business Overview
9.10.5 Novartis Recent Developments
9.11 Merck
9.11.1 Merck Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
9.11.2 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
9.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Market Performance
9.11.4 Merck Business Overview
9.11.5 Merck Recent Developments
10 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Region
10.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast
10.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country
10.2.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Region
10.2.4 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Benign Prostatic Hyperplasia (BPH) Drugs by Country
11 Forecast Market by Type and by Application (2022-2028)
11.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Type (2022-2028)
11.1.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2022-2028)
11.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Type (2022-2028)
11.1.3 Global Forecasted Price of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2022-2028)
11.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Application (2022-2028)
11.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units) Forecast by Application
11.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size (M USD) Forecast by Application (2022-2028)
12 Conclusion and Key Findings
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Benign Prostatic Hyperplasia (BPH) Drugs Market Size (M USD) Comparison by Region (M USD)
Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units) by Manufacturers (2017-2022)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (M USD) by Manufacturers (2017-2022)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2017-2022)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2021)
Table 10. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Average Price (USD/Unit) of Key Manufacturers (2017-2022)
Table 11. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Sales Sites and Area Served
Table 12. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Benign Prostatic Hyperplasia (BPH) Drugs
Table 16. Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
Table 22. Market Restraints
Table 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (K Units)
Table 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type (M USD)
Table 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units) by Type (2017-2022)
Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2017-2022)
Table 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size (M USD) by Type (2017-2022)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Share by Type (2017-2022)
Table 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (USD/Unit) by Type (2017-2022)
Table 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units) by Application
Table 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
Table 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2022) & (K Units)
Table 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2017-2022)
Table 34. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2022) & (M USD)
Table 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application (2017-2022)
Table 36. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Application (2017-2022)
Table 37. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2017-2022) & (K Units)
Table 38. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2017-2022)
Table 39. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2017-2022) & (K Units)
Table 40. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2017-2022) & (K Units)
Table 41. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2017-2022) & (K Units)
Table 42. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2017-2022) & (K Units)
Table 43. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2017-2022) & (K Units)
Table 44. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
Table 45. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
Table 46. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 47. Eli Lilly Business Overview
Table 48. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs SWOT Analysis
Table 49. Eli Lilly Recent Developments
Table 50. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
Table 51. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
Table 52. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 53. GlaxoSmithKline Business Overview
Table 54. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs SWOT Analysis
Table 55. GlaxoSmithKline Recent Developments
Table 56. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
Table 57. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
Table 58. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 59. Astellas Pharma Business Overview
Table 60. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs SWOT Analysis
Table 61. Astellas Pharma Recent Developments
Table 62. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
Table 63. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
Table 64. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 65. Sanofi Business Overview
Table 66. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs SWOT Analysis
Table 67. Sanofi Recent Developments
Table 68. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
Table 69. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
Table 70. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 71. Pfizer Business Overview
Table 72. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs SWOT Analysis
Table 73. Pfizer Recent Developments
Table 74. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
Table 75. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
Table 76. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 77. Abbott Business Overview
Table 78. Abbott Recent Developments
Table 79. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
Table 80. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
Table 81. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 82. Allergan Business Overview
Table 83. Allergan Recent Developments
Table 84. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
Table 85. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
Table 86. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 87. TEVA Business Overview
Table 88. TEVA Recent Developments
Table 89. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
Table 90. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
Table 91. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 92. Mylan Business Overview
Table 93. Mylan Recent Developments
Table 94. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
Table 95. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
Table 96. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 97. Novartis Business Overview
Table 98. Novartis Recent Developments
Table 99. Merck Benign Prostatic Hyperplasia (BPH) Drugs Basic Information
Table 100. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
Table 101. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units), Market Size (M USD), Price (USD/Unit) and Gross Margin (2017-2022)
Table 102. Merck Business Overview
Table 103. Merck Recent Developments
Table 104. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Region (K Units)
Table 105. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Region (M USD)
Table 106. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2022-2028) & (K Units)
Table 107. North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2022-2028) & (M USD)
Table 108. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2022-2028) & (K Units)
Table 109. Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2022-2028) & (M USD)
Table 110. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Region (2022-2028) & (K Units)
Table 111. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Region (2022-2028) & (M USD)
Table 112. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2022-2028) & (K Units)
Table 113. South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2022-2028) & (M USD)
Table 114. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast by Country (2022-2028) & (Units)
Table 115. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Country (2022-2028) & (M USD)
Table 116. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2022-2028) & (K Units)
Table 117. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Type (2022-2028) & (M USD)
Table 118. Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Type (2022-2028) & (USD/Unit)
Table 119. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units) Forecast by Application (2022-2028)
Table 120. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Application (2022-2028) & (M USD)
List of Figures
Figure 1. Product Picture of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size (M USD), 2017-2028
Figure 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size (M USD) (2017-2028)
Figure 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units) & (2017-2028)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Benign Prostatic Hyperplasia (BPH) Drugs Market Size (M USD) by Country (M USD)
Figure 11. Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturers in 2020
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers in 2020
Figure 13. Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 14. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Average Price (USD/Unit) of Key Manufacturers in 2020
Figure 15. The Global 5 and 10 Largest Players: Market Share by Benign Prostatic Hyperplasia (BPH) Drugs Revenue in 2021
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type
Figure 18. Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2017-2022)
Figure 19. Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type in 2021
Figure 20. Market Size Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2017-2022)
Figure 21. Market Size Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type in 2020
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application
Figure 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2017-2022)
Figure 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2021
Figure 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application (2017-2022)
Figure 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2020
Figure 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Application (2017-2022)
Figure 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2017-2022)
Figure 30. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 31. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2020
Figure 32. U.S. Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 33. Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales (K Units) and Growth Rate (2017-2022)
Figure 34. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales (Units) and Growth Rate (2017-2022)
Figure 35. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 36. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2020
Figure 37. Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 38. France Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 39. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 40. Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 41. Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 42. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2020
Figure 44. China Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 45. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 46. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 47. India Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 48. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 49. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (K Units)
Figure 50. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2020
Figure 51. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 52. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 53. Columbia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 54. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2020
Figure 56. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 57. UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 58. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 59. Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 60. South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2017-2022) & (K Units)
Figure 61. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Volume (2017-2028) & (K Units)
Figure 62. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Value (2017-2028) & (M USD)
Figure 63. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Type (2022-2028)
Figure 64. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Type (2022-2028)
Figure 65. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2022-2028)
Figure 66. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share Forecast by Application (2022-2028)
Note: Product cover images may vary from those shown
  • Eli Lilly
  • GlaxoSmithKline
  • Astellas Pharma
  • Sanofi
  • Pfizer
  • Abbott
  • Allergan
  • TEVA
  • Mylan
  • Novartis
  • Merck
Note: Product cover images may vary from those shown

Loading
LOADING...